Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database.
Chronic kidney disease
Claims database
Non-diabetic CKD
Real-world evidence
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
17
01
2022
accepted:
20
04
2022
pubmed:
15
5
2022
medline:
7
2
2023
entrez:
14
5
2022
Statut:
ppublish
Résumé
The observational, real-world evidence FLIEDER study aimed to describe patient clinical characteristics and investigate clinical outcomes in non-diabetic patients with chronic kidney disease (CKD) using data collected from routine clinical practice in the United States. Between 1 January, 2008-31 December, 2018, individuals aged ≥ 18 years, with non-diabetic, stage 3-4 CKD were indexed in the Optum In the main study cohort (N = 504,924), median age was 75.0 years, and 60.5% were female. Most patients (94.7%) had stage 3 CKD at index. Incidence rates for hospitalization for heart failure, the composite kidney outcome, and worsening of CKD stage from baseline were 4.0, 10.3, and 4.4 events/100 patient-years, respectively. The intercurrent event analysis demonstrated that a relative decline in kidney function from baseline significantly increased the risk of cardiorenal events. This real-world study highlights that patients with non-diabetic CKD are at high risk of serious adverse clinical outcomes, and that this risk is amplified in patients who experienced greater post-baseline eGFR decline.
Sections du résumé
BACKGROUND
The observational, real-world evidence FLIEDER study aimed to describe patient clinical characteristics and investigate clinical outcomes in non-diabetic patients with chronic kidney disease (CKD) using data collected from routine clinical practice in the United States.
METHODS
Between 1 January, 2008-31 December, 2018, individuals aged ≥ 18 years, with non-diabetic, stage 3-4 CKD were indexed in the Optum
RESULTS
In the main study cohort (N = 504,924), median age was 75.0 years, and 60.5% were female. Most patients (94.7%) had stage 3 CKD at index. Incidence rates for hospitalization for heart failure, the composite kidney outcome, and worsening of CKD stage from baseline were 4.0, 10.3, and 4.4 events/100 patient-years, respectively. The intercurrent event analysis demonstrated that a relative decline in kidney function from baseline significantly increased the risk of cardiorenal events.
CONCLUSIONS
This real-world study highlights that patients with non-diabetic CKD are at high risk of serious adverse clinical outcomes, and that this risk is amplified in patients who experienced greater post-baseline eGFR decline.
Identifiants
pubmed: 35567698
doi: 10.1007/s40620-022-01340-x
pii: 10.1007/s40620-022-01340-x
pmc: PMC9895008
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-54Informations de copyright
© 2022. The Author(s).
Références
J Am Soc Nephrol. 2019 Sep;30(9):1735-1745
pubmed: 31292197
JAMA Netw Open. 2019 Dec 2;2(12):e1918169
pubmed: 31860111
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
N Engl J Med. 2001 Sep 20;345(12):851-60
pubmed: 11565517
N Engl J Med. 2001 Sep 20;345(12):861-9
pubmed: 11565518
Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1033-1039
pubmed: 28913966
Nephrol Dial Transplant. 2012 Apr;27(4):1454-60
pubmed: 21862458
Lancet. 2011 Jun 25;377(9784):2181-92
pubmed: 21663949
Kidney Int. 2011 Jul;80(1):17-28
pubmed: 21150873
Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711
pubmed: 32862232
J Renin Angiotensin Aldosterone Syst. 2018 Oct-Dec;19(4):1470320318803495
pubmed: 30296880
Clin Kidney J. 2018 Dec;11(6):749-761
pubmed: 30524708
Lancet. 2017 Mar 25;389(10075):1238-1252
pubmed: 27887750
Nat Rev Nephrol. 2020 Apr;16(4):223-237
pubmed: 32024986
N Engl J Med. 1993 Nov 11;329(20):1456-62
pubmed: 8413456
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
N Engl J Med. 2020 Dec 03;383(23):2219-2229
pubmed: 33264825
Pediatr Nephrol. 2016 Mar;31(3):381-91
pubmed: 25980469
N Engl J Med. 2021 Dec 9;385(24):2252-2263
pubmed: 34449181
Pharmacoepidemiol Drug Saf. 2022 Apr;31(4):467-475
pubmed: 34908211
Lancet. 2018 Nov 10;392(10159):2052-2090
pubmed: 30340847
N Engl J Med. 2016 Dec 8;375(23):2293-2297
pubmed: 27959688